Clinical trial
A Double-Blind, Placebo-Controlled Angiographic Study to Evaluate the Effect of Lovastatin on the Progression Rate of Atherosclerosis in the Coronary Arteries of Patients With Coronary Heart Disease
NCT00116870 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Placebo-Controlled Angiographic Study to Evaluate the Effect of Lovastatin on the Progression Rate of Atherosclerosis in the Coronary Arteries of Patients With Coronary Heart Disease
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- June 30, 1985
- Completion date
- February 29, 1992
- Enrollment
- 270
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.